β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study

Table 3 Correlations between serum and antral expression of β-arrestin-2 and different study parameters

	Serum β-Arr-2 level		β-Arr-2 expression in the gastric antrum
	rs	P value	rs	P value
Age	0.101	0.43	0.16	0.14
Child-Pugh class	0.11	0.34	0.08	0.45
INR	0.121	0.19	0.11	0.34
Serum albumin	-0.191	0.07	-0.12	0.26
Serum bilirubin	0.121	0.19	0.03	0.77
Presence of ascites	0.11	0.30	0.14	0.18
Platelets count	-0.381	< 0.001	-0.28	0.008
Baseline EV grade	0.48	< 0.001	0.30	0.004
Baseline PHG grade	0.33	0.002	0.38	< 0.001
Baseline congestion index	0.361	< 0.001	0.32	0.002
Antral β-Arr-2expression	0.72	< 0.001	-	-
Corpus β-Arr-2 expression	0.17	0.10	0.11	0.28
Duodenal β-Arr-2 expression	0.19	0.07	0.13	0.23
AST	-0.231	0.03	-0.25	0.019
APRI score	0.341	< 0.001	0.25	0.039
Non-selective B-blocker dose	0.151	0.15	0.03	0.73

¹Pearson’s correlation. APRI: Aspartate aminotransferase/platelet ratio index; AST: Aspartate aminotransferase; β-Arr-2: β-Arrestin-2; EV: Esophageal varices; INR: International normalization ratio; PHG: Portal hypertensive gastropathy.